
    
      This is an open-label, multicenter study designed to establish the safety and efficacy of
      adalimumab in the treatment of moderate to severely active rheumatoid arthritis. A total of
      100 subjects with inadequate preexisting standard anti-rheumatic therapy were enrolled at 5
      sites in Russia.
    
  